We are enclosing herewith the Press Release on execution and receipt of orders post USFDA approval.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts more than Nifty Microcap 250 and 2.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Veerhealth Care has started executing export orders to a US client in the oral care category after receiving USFDA clearance on May 16, 2025. The company has already shipped 3 FCL (full container load) consignments and received fresh orders to be dispatched within 30 days, targeting 4-5 monthly shipments going forward. Operations are now running at full capacity to meet demand. The company is also in talks with a major Russian corporate group for oral care exports and plans to enter the Russian market soon. Management has guided FY2025-26 revenue of ₹35-40 crore with a 10% PAT margin, and a longer-term target of ₹100 crore revenue with 10% PAT over 24-36 months. They are also exploring the US medical device category and have set up a new hospital care division.
Positive for the stock — USFDA approval unlocks a regulated export market, order execution has begun, and full-capacity operations should support margin recovery after a soft quarter impacted by the inspection process. Investors should note that the FY26 revenue guidance is a significant step-up and execution of monthly repeat orders will be the key thing to track.